BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Parkin induces apoptotic cell death in TNF-α-treated cervical cancer cells

  • Lee, Kyung-Hong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Lee, Min-Ho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kang, Yeo-Wool (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Rhee, Ki-Jong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Tae-Ue (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Yoon-Suk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • Received : 2012.05.11
  • Accepted : 2012.06.04
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Many malignant tumors become resistant to tumor necrosis factor-alpha (TNF-${\alpha}$)-induced cell death during carcinogenesis. In the present study, we examined whether parkin acts as a tumor suppressor in HeLa cells, a human cervical cancer cell line resistant to TNF-${\alpha}$-induced cell death. TNF-${\alpha}$-treatment alone did not affect HeLa cell viability. However, expression of parkin restored TNF-${\alpha}$-induced apoptosis in HeLa cells. Increased cell death was due to the activation of the apoptotic pathway. Expression of parkin in TNF-${\alpha}$-treated HeLa cells stimulated cleavage of the pro-apoptotic proteins caspase-8, -9, -3, -7 and poly ADP ribose polymerase (PARP). In addition, parkin expression resulted in decreased expression of the caspase inhibitory protein, survivin. These results suggest that parkin acts as a tumor suppressor in human cervical cancer cells by modulating survivin expression and caspase activity. We propose that this pathway is a novel molecular mechanism by which parkin functions as a tumor suppressor.

Keywords

References

  1. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S. and Selkoe, D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269. https://doi.org/10.1126/science.1060627
  2. Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K. and Jirtle, R. L. (2000) M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19, 1572-1578. https://doi.org/10.1038/sj.onc.1203437
  3. Oates, A. J., Schumaker, L. M., Jenkins, S. B., Pearce, A. A., DaCosta, S. A., Arun, B. and Ellis, M. J. (1998) The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast. Cancer Res. Treat. 47, 269-281. https://doi.org/10.1023/A:1005959218524
  4. Shridhar, V., Staub, J., Huntley, B., Cliby, W., Jenkins, R., Pass, H. I., Hartmann, L. and Smith, D. I. (1999) A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. Oncogene 18, 3913-3918. https://doi.org/10.1038/sj.onc.1202756
  5. Denison, S. R., Callahan, G., Becker, N. A., Phillips, L. A. and Smith, D. I. (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38, 40-52. https://doi.org/10.1002/gcc.10236
  6. Denison, S. R., Wang, F., Becker, N. A., Schule, B., Kock, N., Phillips, L. A., Klein, C. and Smith, D. I. (2003) Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22, 8370-8378. https://doi.org/10.1038/sj.onc.1207072
  7. Poulogiannis, G., McIntyre, R. E., Dimitriadi, M., Apps, J. R., Wilson, C. H., Ichimura, K., Luo, F., Cantley, L. C., Wyllie, A. H., Adams, D. J. and Arends, M. J. (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc. Natl. Acad. Sci. U.S.A. 107, 15145-15150. https://doi.org/10.1073/pnas.1009941107
  8. Tay, S. P., Yeo, C. W., Chai, C., Chua, P. J., Tan, H. M., Ang, A. X., Yip, D. L., Sung, J. X., Tan, P. H., Bay, B. H., Wong, S. H., Tang, C., Tan, J. M. and Lim, K. L. (2010) Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J. Biol. Chem. 285, 29231-29238. https://doi.org/10.1074/jbc.M110.108241
  9. Veeriah, S., Taylor, B. S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Janakiraman, M., Schultz, N., Hanrahan, A. J., Pao, W., Ladanyi, M., Sander, C., Heguy, A., Holland, E. C., Paty, P. B., Mischel, P. S., Liau, L., Cloughesy, T. F., Mellinghoff, I. K., Solit, D. B. and Chan, T. A. (2010) Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet. 42, 77-82. https://doi.org/10.1038/ng.491
  10. Wang, F., Denison, S., Lai, J. P., Philips, L. A., Montoya, D., Kock, N., Schule, B., Klein, C., Shridhar, V., Roberts, L. R. and Smith, D. I. (2004) Parkin gene alterations in hepatocellular carcinoma. Genes. Chromosomes. Cancer 40, 85-96. https://doi.org/10.1002/gcc.20020
  11. Agirre, X., Roman-Gomez, J., Vazquez, I., Jimenez-Velasco, A., Garate, L., Montiel-Duarte, C., Artieda, P., Cordeu, L., Lahortiga, I., Calasanz, M. J., Heiniger, A., Torres, A., Minna, J. D. and Prosper, F. (2006) Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int. J. Cancer 118, 1945-1953. https://doi.org/10.1002/ijc.21584
  12. Picchio, M. C., Martin, E. S., Cesari, R., Calin, G. A., Yendamuri, S., Kuroki, T., Pentimalli, F., Sarti, M., Yoder, K., Kaiser, L. R., Fishel, R. and Croce, C. M. (2004) Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin. Cancer Res. 10, 2720-2724. https://doi.org/10.1158/1078-0432.CCR-03-0086
  13. Wang, H., Liu, B., Zhang, C., Peng, G., Liu, M., Li, D., Gu, F., Chen, Q., Dong, J. T., Fu, L. and Zhou, J. (2009) Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J. Pathol. 218, 76-85. https://doi.org/10.1002/path.2512
  14. Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867. https://doi.org/10.1038/nature01322
  15. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. and Baldwin, A. S., Jr. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683. https://doi.org/10.1126/science.281.5383.1680
  16. Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., Ulevitch, R. and Cerami, A. (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316, 552-554. https://doi.org/10.1038/316552a0
  17. Aggarwal, B. B. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756. https://doi.org/10.1038/nri1184
  18. Shin, D. H., Park, K. W., Wu, L. C. and Hong, J. W. (2011) ZAS3 promotes TNFalpha-induced apoptosis by blocking NFkappaB-activated expression of the anti-apoptotic genes TRAF1 and TRAF2. BMB Rep. 44, 267-272. https://doi.org/10.5483/BMBRep.2011.44.4.267
  19. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA. Cancer J. Clin. 61, 69-90. https://doi.org/10.3322/caac.20107
  20. Mehdi, S. J., Alam, M. S., Batra, S. and Rizvi, M. M. (2011) Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma. Med. Oncol. 28, 1520-1526. https://doi.org/10.1007/s12032-010-9633-x
  21. Franco, D. L., Nojek, I. M., Molinero, L., Coso, O. A. and Costas, M. A. (2002) Osmotic stress sensitizes naturally resistant cells to TNF-alpha-induced apoptosis. Cell Death Differ. 9, 1090-1098. https://doi.org/10.1038/sj.cdd.4401074
  22. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S. and Dixit, V. M. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81, 801-809. https://doi.org/10.1016/0092-8674(95)90541-3
  23. Nunez, G., Benedict, M. A., Hu, Y. and Inohara, N. (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17, 3237-3245. https://doi.org/10.1038/sj.onc.1202581
  24. Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G. and Alnemri, E. S. (1996) In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD- like domains. Proc. Natl. Acad. Sci. U.S.A 93, 7464-7469. https://doi.org/10.1073/pnas.93.15.7464
  25. Park, S. J., Shin, J. H., Kang, H., Hwang, J. J. and Cho, D. H. (2011) Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep. 44, 517-522. https://doi.org/10.5483/BMBRep.2011.44.8.517
  26. Igney, F. H. and Krammer, P. H. (2002) Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288. https://doi.org/10.1038/nrc776
  27. Sah, N. K., Khan, Z., Khan, G. J. and Bisen, P. S. (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett. 244, 164-171. https://doi.org/10.1016/j.canlet.2006.03.007
  28. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
  29. Chen, G. and Goeddel, D. V. (2002) TNF-R1 signaling: a beautiful pathway. Science 296, 1634-1635. https://doi.org/10.1126/science.1071924
  30. Friedrichs, B., Siegel, S., Andersen, M. H., Schmitz, N. and Zeis, M. (2006) Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk. Lymphoma. 47, 978-985. https://doi.org/10.1080/10428190500464062
  31. Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P. H., Shimizu, N., Tanaka, K., Mizuno, Y. and Hattori, N. (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem. Biophys. Res. Commun. 332, 233-240. https://doi.org/10.1016/j.bbrc.2005.04.124
  32. Staropoli, J. F. (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30, 719-727. https://doi.org/10.1002/bies.20784
  33. Springer, W. and Kahle, P. J. (2011) Regulation of PINK1-Parkin-mediated mitophagy. Autophagy 7, 266-278. https://doi.org/10.4161/auto.7.3.14348
  34. Kim, Y. S., Patel, S. and Lee, S. J. (2006) Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates. Exp. Neurol. 197, 538-541. https://doi.org/10.1016/j.expneurol.2005.10.024

Cited by

  1. Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317695025
  2. Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells vol.171, pp.7, 2013, https://doi.org/10.1007/s12010-013-0443-4
  3. Parkin induces G2/M cell cycle arrest in TNF-α-treated HeLa cells vol.464, pp.1, 2015, https://doi.org/10.1016/j.bbrc.2015.05.101
  4. Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis vol.19, pp.2, 2017, https://doi.org/10.1016/j.neo.2016.12.006
  5. Generation of Mouse Haploid Somatic Cells by Small Molecules for Genome-wide Genetic Screening vol.20, pp.9, 2017, https://doi.org/10.1016/j.celrep.2017.07.081
  6. Apoptosis induction of human prostate carcinoma cells by cordycepin through reactive oxygen species-mediated mitochondrial death pathway vol.42, pp.3, 2013, https://doi.org/10.3892/ijo.2013.1762
  7. Parkin Sensitizes toward Apoptosis Induced by Mitochondrial Depolarization through Promoting Degradation of Mcl-1 vol.9, pp.4, 2014, https://doi.org/10.1016/j.celrep.2014.10.046
  8. Saikosaponin-d Enhances the Anticancer Potency of TNF-αvia Overcoming Its Undesirable Response of Activating NF-Kappa B Signalling in Cancer Cells vol.2013, 2013, https://doi.org/10.1155/2013/745295
  9. Ketoconazole induces apoptosis in rat cardiomyocytes through reactive oxygen species-mediated parkin overexpression vol.89, pp.10, 2015, https://doi.org/10.1007/s00204-015-1502-0
  10. Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway vol.45, pp.2, 2014, https://doi.org/10.3892/ijo.2014.2463
  11. An emerging role of PARK2 in cancer vol.92, pp.1, 2014, https://doi.org/10.1007/s00109-013-1107-0
  12. Wilms’ tumor gene 1 enhances nutlin-3-induced apoptosis vol.31, pp.1, 2014, https://doi.org/10.3892/or.2013.2832
  13. Induction of apoptosis by sarijang, a bamboo salt sauce, in U937 human leukemia cells through the activation of caspases vol.6, pp.2, 2013, https://doi.org/10.3892/etm.2013.1151
  14. Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson's disease by using proteomic and molecular approaches vol.85-86, 2015, https://doi.org/10.1016/j.neuint.2015.03.007
  15. The Mitochondrial Dynamism-Mitophagy-Cell Death Interactome vol.116, pp.1, 2015, https://doi.org/10.1161/CIRCRESAHA.116.303554
  16. The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis vol.7, pp.10, 2018, https://doi.org/10.3390/cells7100154
  17. Parkin in Parkinson’s Disease and Cancer: a Double-Edged Sword vol.55, pp.8, 2018, https://doi.org/10.1007/s12035-018-0879-1